A number of investment brokers have recently updated their price targets on shares of BIND Therapeutics, Inc. (NASDAQ:BIND). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

05/02/2016 – BIND Therapeutics, Inc. was downgraded to “hold” by analysts at Stifel Nicolaus. They now have a USD 3.75 price target on the stock.

04/07/2016 – BIND Therapeutics, Inc. was downgraded to “market perform” by analysts at Cowen.

04/07/2016 – BIND Therapeutics, Inc. was downgraded to “perform” by analysts at Oppenheimer.

04/07/2016 – BIND Therapeutics, Inc. had its “market perform” rating reiterated by analysts at JMP Securities.

05/12/2015 – BIND Therapeutics, Inc. was upgraded to “buy” by analysts at Zacks. They now have a USD 7 price target on the stock.

12/04/2014 – BIND Therapeutics, Inc. was downgraded to “neutral” by analysts at Credit Suisse. They now have a USD 10 price target on the stock.

The share price of BIND Therapeutics, Inc. (NASDAQ:BIND) was down -13.64% during the last day of trading, with a day high of 0.65. 1945655 shares were traded during the last session.

The stock’s 50 day moving average is 1.61 and its 200 day moving average is 2.53. The stock’s market capitalization is 11.85M. BIND Therapeutics, Inc. has a 52-week low of 0.35 and a 52-week high of 6.45.

View other investors thoughts on BIND Therapeutics, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.